Quantifying the changes in the tumour vascular micro-environment in spinal metastases treated with stereotactic body radiotherapy - a single arm prospective study
Open Access
- 1 December 2022
- journal article
- research article
- Published by Walter de Gruyter GmbH in Radiology and Oncology
- Vol. 56 (4) , 525-534
Abstract
Background: The primary objective was to quantify changes in vascular micro-environment in spinal metastases (SM) patients treated with stereotactic body radiotherapy (SBRT) with multi-parametric dynamic contrast enhanced (DCE) magnetic resonance imaging (MRI). The secondary objective was to study plasma biomarkers related to endothelial apoptosis. Patients and methods: Patients were imaged with DCE-MRI at baseline/1-week/12-weeks post-SBRT. Metrics including normalised time-dependent leakage (Ktrans), permeability surface product (PS), fractional plasma volume (Vp), extracellular volume (Ve) and perfusion (F) were estimated using distributed parameter model. Serum acid sphingomyelinase (ASM) and sphingosine-1-phosphate (S1P) were quantified using ELISA. Clinical outcomes including physician-scored and patient-reported toxicity were collected. Results: Twelve patients (with varying primary histology) were recruited, of whom 10 underwent SBRT. Nine patients (with 10 lesions) completed all 3 imaging assessment timepoints. One patient died due to pneumonia (unrelated) before follow-up scans were performed. Median SBRT dose was 27 Gy (range: 24–27) over 3 fractions (range: 2–3). Median follow-up for alive patients was 42-months (range: 22.3–54.3), with local control rate of 90% and one grade 2 or higher toxicity (vertebral compression fracture). In general, we found an overall trend of reduction at 12-weeks in all parameters (Ktrans/PS/Vp/Ve/F). Ktrans and PS showed a reduction as early as 1-week. Ve/Vp/F exhibited a slight rise 1-week post-SBRT before reducing below the baseline value. There were no significant changes, post-SBRT, in plasma biomarkers (ASM/S1P). Conclusions: Tumour vascular micro-environment (measured by various metrics) showed a general trend towards downregulation post-SBRT. It is likely that vascular-mediated cell killing contributes to excellent local control rates seen with SBRT. Future studies should evaluate the effect of SBRT on primary-specific spinal metastases (e.g., renal cell carcinoma).Keywords
This publication has 19 references indexed in Scilit:
- Models and methods for analyzing DCE‐MRI: A reviewMedical Physics, 2014
- Radiobiological basis of SBRT and SRSInternational Journal of Clinical Oncology, 2014
- Measurement of Blood Perfusion in Spinal Metastases With Dynamic Contrast-Enhanced Magnetic Resonance ImagingSpine, 2013
- Probabilities of Radiation Myelopathy Specific to Stereotactic Body Radiation Therapy to Guide Safe PracticeInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2013
- International Spine Radiosurgery Consortium Consensus Guidelines for Target Volume Definition in Spinal Stereotactic RadiosurgeryInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Fundamentals of tracer kinetics for dynamic contrast‐enhanced MRIJournal of Magnetic Resonance Imaging, 2011
- Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCISTJournal of Cancer, 2010
- Clinical Features of Metastatic Bone Disease and Risk of Skeletal MorbidityClinical Cancer Research, 2006
- Elevated sphingomyelinase activity and ceramide concentration in serum of patients undergoing high dose spatially fractionated radiation treatment: Implications for endothelial apoptosisCancer Biology & Therapy, 2005
- Tumor Response to Radiotherapy Regulated by Endothelial Cell ApoptosisScience, 2003